EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY

Yoon-Koo Kang iD, Hyung-Don Kim iD, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young-Woo Kim, Jin Young Kim iD, Min-Hee Ryu iD, Sun Young Rha iD, Ik Joo Chung iD, In-Ho Kim iD, Sang Cheul Oh und 23 weitere

Journal of Clinical Oncology · 2024-09 · 42 (25) · 2961-2965

DOI: 10.1200/jco.23.02167 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024-09. Verfasst von Yoon-Koo Kang und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Tegafur, Docetaxel, Oxaliplatin. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The phase III PRODIGY study demonstrated that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 chemotherapy (CSC) improved progression-free survival (PFS) compared with surgery followed by adjuvant S-1 (SC) for patients with resectable locally advanced gastric cancer (LAGC) with clinical T2-3N+ or T4Nany disease. The primary end point was PFS. Overall survival (OS) was the secondary end point. We herein report the long-term follow-up outcomes, including OS, from this trial. A total of 238 and 246 patients were randomly assigned to the CSC and SC arms, respectively, and were treated (full analysis set). As of the data cutoff (September 2022), the median follow-up duration of the surviving patients was 99.5 months. Compared with SC, CSC significantly increased the OS (adjusted hazard ratio [HR], 0.72; stratified log-rank P = .027) with an 8-year OS rate of 63.0% and 55.1% for the CSC and SC arms, respectively. CSC also significantly improved the PFS (HR, 0.70; stratified log-rank P = .016). In conclusion, neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, prolonged the OS of Asian patients with LAGC relative to patients treated with surgery and adjuvant S-1. It should be considered one of the standard treatment options for patients with LAGC in Asia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTegafurDocetaxelOxaliplatinOxonic AcidDrug CombinationsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedChemotherapy, AdjuvantAgedAdultGastrectomy

Substanzen

TegafurDocetaxelOxaliplatinOxonic AcidS 1 (combination)Drug Combinations

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Surgery, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea.
  • Department of Surgery, Chonnam National University Medical School, Hwasun, Republic of Korea.
  • Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Center for Gastric Cancer, Research Institute & Hospital, National Cancer Center, Graduate School of Cancer Science and Policy, Goyang, Republic of Korea.
  • Division of Hemato-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.

ORCID-Profile: Yoon-Koo Kang, Hyung-Don Kim, Jin Young Kim, Min-Hee Ryu, Sun Young Rha, Ik Joo Chung, In-Ho Kim, Young Soo Park, Jae-Ho Cheong, Oh Jeong, Mi Hwa Heo, Hark Kyun Kim, Dae Young Zang, You Jin Jang, Beom Su Kim, Seung Wan Ryu, Myeong-Cherl Kook, Baek-Yeol Ryoo, Hyunki Kim, Sung Hoon Noh

Zitieren

APA

Kang, Y. K., Kim, H. D., Yook, J. H., Park, Y. K., Lee, J. S., Kim, Y. W., Kim, J. Y., Ryu, M. H., Rha, S. Y., Chung, I. J., Kim, I. H., Oh, S. C., Park, Y. S., Cheong, J. H., Jeong, O., Heo, M. H., Kim, H. K., Park, C., Yoo, C. H., …, & Noh, S. H. (2024). Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY. Journal of Clinical Oncology, 42(25), 2961-2965. https://doi.org/10.1200/jco.23.02167

Vancouver

Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, et al. Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY. Journal of Clinical Oncology. 2024;42(25):2961-2965. doi:10.1200/jco.23.02167

BibTeX
@article{Kang2024,
  author = {Kang, Yoon-Koo and Kim, Hyung-Don and Yook, Jeong Hwan and Park, Young-Kyu and Lee, Jong Seok and Kim, Young-Woo and Kim, Jin Young and Ryu, Min-Hee and Rha, Sun Young and Chung, Ik Joo and Kim, In-Ho and Oh, Sang Cheul and Park, Young Soo and Cheong, Jae-Ho and Jeong, Oh and Heo, Mi Hwa and Kim, Hark Kyun and Park, ChoHyun and Yoo, Chang Hak and Kang, Seok Yun and Zang, Dae Young and Jang, You Jin and Sul, Ji Young and Kim, Jong Gwang and Kim, Beom Su and Beom, Seung-Hoon and Hwang, Jun-Eul and Ryu, Seung Wan and Kook, Myeong-Cherl and Ryoo, Baek-Yeol and Kim, Hyunki and Yoo, Moon-Won and Lee, Nam Su and Lee, Sang Ho and Noh, Sung Hoon},
  title = {Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {25},
  pages = {2961--2965},
  doi = {10.1200/jco.23.02167}
}
Kostenlos starten →